Abstracts tagged "Dermatology"

Abstract Number: 1779 • ACR Convergence 2021
A Comparison of Quality of Life Outcomes Between Psoriatic Arthritis and Psoriasis Patients: Data from the Brigham Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Nancy Shadick¹, Kumiko Schnock², Vivi Feather², Jing Cui³, Gabriela Maica², Alexa Marshall², Wynona Francis², Muibat Yussuff², Lourdes Maria Perez Chada², Michael E. Weinblatt² and Joseph Merola⁴, ¹Brigham & Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: To report the demographics, clinical characteristics, and differential impacts on quality of life measures among participants in the Psoriasis (PsO) and Psoriatic Arthritis (PsA)…
Abstract Number: 1796 • ACR Convergence 2021
Early Identification of Psoriatic Arthritis with Axial Involvement Among Patients with Psoriasis: A Prospective Multicenter Study
Fabian Proft¹, Susanne Lüders², Theresa Hunter³, Gustavo Luna⁴, Valeria Rios Rodriguez¹, Mikhail Protopopov¹, Katharina Meier⁵, Georgios Kokolakis⁵, Kamran Ghoreschi⁵ and Denis Poddubnyy⁶, ¹Charité University Medicine Berlin, Berlin, Germany, ²Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ³Eli Lilly and Company, Indianapolis, IN, USA, Indianapolis, IN, ⁴ICON plc, Stockholm, Sweden, ⁵Department of Dermatology, Venereology and Allergology – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, Berlin, Germany, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: In the absence of reliable serological and/or imaging biomarkers for early psoriatic arthritis (PsA) and an existing diagnostic delay there is a need for…
Abstract Number: 1822 • ACR Convergence 2021
Relationships Between Dermatologic Symptoms and Health-related Quality of Life in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Peter C Taylor¹, Andrew G Bushmakin², Joseph C Cappelleri², Pamela Young³, Rebecca Germino², Joseph Merola⁴ and Gil Yosipovitch⁵, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA, ⁴Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ⁵University of Miami Miller School, Florida, FL
Background/Purpose: Dermatologic symptoms of PsA can substantially impact patient (pt) health‑related quality of life (HRQoL);1 itch is the most commonly reported, and among the most…
Abstract Number: 0184 • ACR Convergence 2021
Phase III, Randomized Trial Comparing Clinical Outcomes Between Patients with Moderate-to-severe Chronic Plaque Psoriasis Receiving Adalimumab Reference Product (RP) Continuously versus Those Who Switched Between BI 695501 and Adalimumab RP
Alan Menter¹, Dorothy McCabe², Benjamin Lang³, Jennifer Schaible⁴ and Sravan Kumar Eduru⁵, ¹Baylor Scott & White, Dallas, TX, ²Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany, ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Boberach, Germany, ⁵(Formerly at) Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany
Background/Purpose: BI 695501 is a FDA-approved biosimilar to adalimumab RP (AbbVie), and is approved in seven indications, including rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis,…
Abstract Number: 0205 • ACR Convergence 2021
An Observational Study from the Perspective of Rheumatology in the Management of Patients with Psoriatic Arthritis in Turkey – LOOP Study
Ediz Dalkilic¹, Dilek Solmaz², Orhan Kucuksahin³, Erhan Capkin⁴, Mehmet Emin Derin⁵, Didem Arslan⁶, Fatih Noyan⁷, Nihan Belkis Coskun¹, Sadiye Murat⁸, Omer Faruk Sendur⁹, Meltem Alkan Melikoglu¹⁰, Savas Gursoy¹¹, Taciser Kaya¹², Ali Sahin¹³, Murat Karkucak⁴, Timur Pirildar¹⁴, Mustafa Ender Terzioglu¹⁵, Cemal Bes¹⁶ and Servet Akar², ¹Uludag University, School of Medicine – Bursa, Turkey, Bursa, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ³Ankara State Hospital, School of Medicine, Ankara, Turkey, ⁴Karadeniz Technical University, School of Medicine, Trabzon, Turkey, ⁵Sivas Numune Hospital, Sivas, Turkey, ⁶Cukurova University, School of Medicine – Adana, Turkey, Adana, Turkey, ⁷Nazilli State Hospital – Aydın, Turkey, Aydin, Turkey, ⁸Istanbul Medeniyet University, Goztepe Training and Research Hospital, İstanbul, Turkey, ⁹Adnan Menderes University, School of Medicine, Aydin, Turkey, ¹⁰Ataturk University, School of Medicine, Erzurum, Turkey, ¹¹Gaziantep University, School of Medicine – Gaziantep, Turkey, Gaziantep, Turkey, ¹²Saglik Bilimleri University, Izmır Bozyaka Trainig and Research Hospital – Izmir, Turkey, Izmir, Turkey, ¹³Sivas Cumhuriyet University, School of Medicine, Sivas, Turkey, ¹⁴Celal Bayar University, School of Medicine – Manisa, Turkey, Manisa, Turkey, ¹⁵Akdeniz University, School of Medicine, Antalya, Turkey, ¹⁶Saglik Bilimleri University, Basaksehir Cam and Sakura State Hospital – Istanbul, Turkey, Istanbul, Turkey
Background/Purpose: Available evidence suggests that timely and effective management of patients with psoriatic arthritis (PsA) can improve long-term outcomes. Current information on the factors which…
Abstract Number: 0513 • ACR Convergence 2021
Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood
DeAnna Diaz¹, Thomas Vazquez², Christina Bax³, Jay Patel⁴, Madison Grinnell⁵, Emily Keyes⁶, Yubin Li⁵ and Victoria Werth⁷, ¹Philadelphia College of Medicine, Philadelphia, PA, ²FIU Wertheim College of Medicine, Virginia Beach, VA, ³Corporal Michael J. Crescenz VAMC/ Department of Dermatology, U Penn, Philadelphia, PA, ⁴Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, NJ, ⁵Corporal Michael J. Crescenz VAMC, Department of Dermatology, U Penn, Philadelphia, PA, ⁶Department of Dermatology, Perelman School of Medicine at the University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Our group has previously shown that Spirulina, a popular herbal supplement with purported immune boosting effects, is temporally associated with dermatomyositis (DM) onset and…
Abstract Number: 0170 • ACR Convergence 2020
Utilizing Design Thinking to Develop a Decision Aid for Patients with Psoriasis and Psoriatic Arthritis
Marilyn Wan¹, Michele Almonte², Joel Gelfand¹ and Alexis Ogdie², ¹University of Pennsylvania, Philadelphia, ²University of Pennsylvania, Philadelphia, PA
Background/Purpose: Given the complexity of available treatment recommendations, patients with psoriatic disease would benefit from a process fostering shared decision-making using a patient-centered approach. True…
Abstract Number: 0278 • ACR Convergence 2020
Trends in Incidence of Cutaneous Lupus Erythematosus from 1976 to 2018: A Population-Based Study
Mehmet Hocaoglu¹, Mark Denis P. Davis², Shirley-Ann Osei-Onomah³, Jesse Dabit², Rachel Giblon², Thomas O'Byrne², Cynthia Crowson⁴ and Ali Duarte-Garcia², ¹University of Maryland Medical Center Midtown Campus, Baltimore, MD, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, ⁴Mayo Clinic, Rochester, Minnesota, USA, Rochester, MN
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a heterogeneous chronic disease with potential for long lasting morbidity. Studies that provide incidence data on the entire spectrum…
Abstract Number: 0378 • ACR Convergence 2020
Itch as the Major Mediator of the Effect of Tofacitinib on Health-Related Quality of Life in Psoriatic Arthritis: A Mediation Analysis
Joseph Merola¹, Peter Taylor², Andrew Bushmakin³, Joseph Cappelleri³, Pamela Young⁴, Rebecca Germino⁵ and Gil Yosipovitch⁶, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc, Groton, CT, ⁴Pfizer Inc, Collegeville, PA, ⁵Pfizer Inc, New York, NY, ⁶University of Miami, Miami, FL
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, systemic inflammatory disease with signs and symptoms across multiple domains, including cutaneous manifestations, which can impact health-related quality…
Abstract Number: 0500 • ACR Convergence 2020
Genomic, Phenomic, Proteomic Predictors of Psoriatic Arthritis
Jessica Walsh¹, Sophie Belman², Courtney Carroll², Michael Milliken², Benjamin Haaland², Kristina Callis Duffin², Gerald Krueger² and Bing-jian Feng², ¹University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT
Background/Purpose: Delays in diagnosis of psoriatic arthritis (PsA) are common and impair quality of life and function. The study objective was to identify phenotypes, genetic…
Abstract Number: 0849 • ACR Convergence 2020
Herpes Zoster Events with Anifrolumab in Patients with Active SLE: An Integrated Analysis of Phase 2 and Phase 3 Trials
Joan Merrill¹, Kenneth Kalunian², Richard Furie³, Kevin Winthrop⁴, Patricia Primakov⁵, Lilia Pineda⁶, Gabriel Abreu⁷ and Raj Tummala⁶, ¹Oklahoma Medical Research Foundation, Oklahoma City, ²School of Health Sciences, University of California, La Jolla, ³Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Oregon Health & Science University, Portland, OR, ⁵BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, ⁷BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Background/Purpose: In the phase 2 MUSE and phase 3 TULIP-1 and TULIP-2 trials, treatment with anifrolumab, a monoclonal antibody to the type I interferon receptor,…
Abstract Number: 1063 • ACR Convergence 2020
Spirulina Stimulates Inflammatory Cytokine Production Through the STING and TLR Pathways in Dermatomyositis in Vitro
Christina Bax¹, Yubin Li¹, Spandana Maddukuri², Adarsh Ravishankar³, Jay Patel³, Daisy Yan¹, Josef Symon Concha¹ and Victoria Werth¹, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia
Background/Purpose: Spirulina, a popular herbal supplement, stimulates the immune system, as determined by in vitro and in vivo studies. Our recent epidemiologic data suggest that Spirulina…
Abstract Number: 1404 • ACR Convergence 2020
Investigating the Dermatomyositis Skin Inflammatory Infiltrate Using Image Mass Cytometry
Jay Patel¹, Spandana Maddukuri², Yubin Li³, Christina Bax⁴ and Victoria Werth³, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA, ⁴University of Pennsylvania, Department of Dermatology, Philadelphia
Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease affecting the skin and muscles, among other organs. The inflammatory infiltrate in skin has not been fully…
Abstract Number: 1405 • ACR Convergence 2020
Evaluating the Cellular Composition of Anti-synthetase Syndrome and Dermatomyositis Skin Lesions Using Image Mass Cytometry
Jay Patel¹, Adarsh Ravishankar¹, Spandana Maddukuri², Christina Bax³ and Victoria Werth⁴, ¹University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, ²University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Montville, NJ, ³University of Pennsylvania, Department of Dermatology, Philadelphia, ⁴University of Pennsylvania and the Michael J. Crescenz VA Medical Center, Philadelphia, PA
Background/Purpose: Antisynthetase syndrome (AS) is a systemic autoimmune disorder characterized by the presence of anti-aminoacyl-tRNA synthetase antibodies, myositis, interstitial lung disease (ILD), mechanics hands, and…
Abstract Number: 1560 • ACR Convergence 2020
Measuring Asymmetry in Facial Morphea via 3D Stereophotogrammetry
Laila Abbas¹, Jennifer Day² and Heidi Jacobe³, ¹UT Southwestern Medical Center, Dallas, TX, ²University of Colorado, Denver, CO, ³University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Morphea is an autoimmune disorder causing sclerosis and inflammation of the skin and subcutaneous tissue. Facial morphea can cause substantial disfigurement and negative impact on quality of life. Existing clinical measures such…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].